The aim of this technology assessment, which has been commissioned by NICE through the NIHR SR Programme as part of the NICE Single Technology Appraisal process, is to review the submission received from the Recordati Rare Disease/Helsinn Healthcare on the clinical and cost-effectiveness evidence of Chlormethine gel (Ledaga®) for treating mycosis fungoides-type cutaneous T-cell lymphoma in adults. The primary source of clinical effectiveness evidence submitted by Recordati Rare Disease/Helsinn Healthcare consists of a Phase II RCT (Study 201) comparing Chlormethine gel with Chlormethine ointment. The Aberdeen HTA Group acts as the Evidence Review Group (ERG) for this technology appraisal and provides an independent critique of the clinical and cost-effectiveness evidence submitted by the company. Based on the findings of the submission received from the company and the ERG’s critique, NICE will release appropriate clinical guidance. For more information see: https://www.nice.org.uk/guidance/indevelopment/gid-ta10481
Contacts
- Miriam Brazzelli; m.brazzelli@abdn.ac.uk